Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07D213/81—Amides; Imides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
  • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
  • C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
  • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/88—Carboxylic acid amides having nitrogen atoms of carboxamide groups bound to an acyclic carbon atom and to a carbon atom of a six-membered aromatic ring wherein at least one ortho-hydrogen atom has been replaced
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C327/00—Thiocarboxylic acids
  • C07C327/38—Amides of thiocarboxylic acids
  • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
  • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D215/38—Nitrogen atoms
  • C07D215/40—Nitrogen atoms attached in position 8
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
  • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
  • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
  • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
  • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2602/00—Systems containing two condensed rings
  • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
  • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
  • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

• the present invention relates to novel compounds having retinoid-li e biological activity. More specifically, the present invention relates to amides formed between aryl or heteroryl amines and tetrahydronaphthalene, chroman, thiochroman and 1 , 2 ,3,4-tetrahydroquinoline carboxylic acids where at least one of the aromatic or heteroaromatic moieties of the amide bears an electron withdrawing substituent.
• the compounds are agonists of RAR retinoid receptors .
• Background Art Compounds which have retinoid-like activity are well known in the art, and are described in numerous United States and other patents and in scientific publications.
• compositions having a retinoid-like compound or compounds as the active ingredient are useful as regulators of cell proliferation and differentiation, and particularly as agents for treating skin-related diseases, including, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hyperproliferative disorders of the skin, eczema, atopic dermatitis, Darriers disease, lichen planus, prevention and reversal of glucocorticoid damage (steroid atrophy), as a topical anti-microbial, as skin anti-pigmentation agents and to treat and reverse the effects of age and photo damage to the skin.
• skin-related diseases including, actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne, psoriasis, ichthyoses and other keratinization and hyperproliferative disorders of the skin, eczem
• Retinoid compounds are also useful for the prevention and treatment of cancerous and precancerous conditions, including, premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the treatment of Kaposi's sarcoma.
• premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the treatment of
• retinoid compounds can be used as agents to treat diseases of the eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well as in the treatment and prevention of various cardiovascular diseases, including, without limitation, diseases associated with lipid metabolism such as dyslipidemias, prevention of post-angioplasty restenosis and as an agent to increase the level of circulating tissue plasminogen activator (TPA) .
• PVR proliferative vitreoretinopathy
• TPA tissue plasminogen activator
• retinoid compounds include the prevention and treatment of conditions and diseases associated with human papilloma virus (HPV), including warts and genital warts, various inflammatory diseases such as pulmonary fibrosis, ileitis, colitis and Krohn's disease, neurodegenerative diseases such as Alzheimer's ⁇ disease, Parkinson's disease and stroke, improper
• the present invention provides compounds having retinoid-like biological activity and specifically compounds which are agonists of one or more RAR retinoid receptor subtypes.
• the present invention covers compounds of Formula 1
• X is [C(R 1 ) 2 ] n where n is an integer between 0 and 2;
• R x is independently H or alkyl of 1 to 6 carbons
• R 2 is hydrogen, or lower alkyl of 1 to 6 carbons
• R 3 is hydrogen, lower alkyl of 1 to 6 carbons or F; m is an integer having the value of 0 - 2; o is an integer having the value of 0 - 4; ⁇ p is an integer having the value of 0 - 2;
• 2 r is an integer having the value 0 - 2 with the
• 5 Y is a phenyl or naphthyl group, or heteroaryl
• 1 W is a substituent selected from the group 2 consisting of F, Br, Cl, I, C-alkyl, fluoro 3 substituted x _ 6 alkyl, N0 2 , N 3 , OH, OCH 2 OCH 3 , 4 OC- ⁇ jo alkyl, tetrazol, CN, S0 2 C 1 _ 6 -alkyl , S0 2 C 1 _ 6 -alkyl, s alkyl, 6 CO-C ⁇ alkyl, COOR 8 , phenyl, phenyl itself substituted 7 with a W group other than with phenyl or substituted 8
• R ⁇ is lower alkyl, phenyl or lower
• R 12 is lower alkyl
• R 13 is divalent
• this invention relates to ⁇ the use of the compounds of Formula 1 for the
• the compounds are also useful for the prevention and treatment of cancerous and 1 precancerous conditions, including, premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the treatment of Kaposi's sarcoma.
• premalignant and malignant hyperproliferative diseases such as cancers of the breast, skin, prostate, cervix, uterus, colon, bladder, esophagus, stomach, lung, larynx, oral cavity, blood and lymphatic system, metaplasias, dysplasias, neoplasias, leukoplakias and papillomas of the mucous membranes and in the treatment of Kaposi'
• the present compounds can be used as agents to treat diseases of the eye, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well as in the treatment and prevention of various ⁇ cardiovascular diseases, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well as in the treatment and prevention of various ⁇ cardiovascular diseases, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well as in the treatment and prevention of various ⁇ cardiovascular diseases, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well as in the treatment and prevention of various ⁇ cardiovascular diseases, including, without limitation, proliferative vitreoretinopathy (PVR), retinal detachment, dry eye and other corneopathies, as well as in
• TPA tissue plasminogen e activator
• human papilloma virus including warts and o genital warts, various inflammatory diseases such as i pulmonary fibrosis, ileitis, colitis and Krohn's 2 disease, neurodegenerative diseases such as 3 Alzheimer's disease, Parkinson's disease and stroke, 4 improper pituitary function, including insufficient 5 production of growth hormone, modulation of 6 apoptosis, including both the induction of apoptosis 7 and inhibition of T-Cell activated apoptosis, s restoration of hair growth, including combination 9 therapies with the present compounds and other 0 agents such as Minoxidil R , diseases associated with 1 the immune system, including use of the present 2 compounds as immunosuppressants and 3 immunostimulants, modulation of organ transplant 4 rejection and facilitation of wound healing, 5 including modulation of chelosis.
• HPV human papilloma virus
• This invention also relates to a pharmaceutical 7 formulation comprising a compound of Formula 1 in 8 admixture with a pharmaceutically acceptable 9 excipient.
• this invention relates to 1 processes for making a compound of Formula 1 which processes comprise reacting, in the presence of an acid acceptor or water acceptor, a compound of Formula 2 with a compound of Formula 3 or a compound of Formula 2a with a compound of Formula 3a where X x is OH, halogen, or other group which renders the -COX i group reactive for amide formation, and where the remaining symbols are defined as in connection with Formula 1.
• the present invention relates to such reactions performed on the compounds of Formula 1 which cause transformations of the B group while the reaction product still remains within the scope of Formula 1.
• alkyl refers to and covers any and all
• alkenyl refers to and covers normal alkenyl, branch
• alkynyl refers to and covers normal alkynyl, and ⁇ branch chain alkynyl groups having one or more
• Lower alkyl means the above-defined broad ii definition of alkyl groups having 1 to 6 carbons in
• Lower alkenyl is defined similarly having 2
• esters refers to and 2 covers any compound falling within the definition of 3 that term as classically used in organic chemistry.
• B 5 of Formula 1 is -COOH
• this term covers the products 6 derived from treatment of this function with 7 alcohols or thioalcohols preferably with aliphatic 8 alcohols having 1-6 carbons.
• the ester is 9 derived from compounds where B is -CH 2 0H, this term
• esters 30 covers compounds derived from organic acids capable 1 of forming esters including phosphorous based and 2 sulfur based acids, or compounds of the formula 3 -CH 2 0C0R 1;l where R xl is any substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aliphatic aromatic group, preferably with 1-6 carbons in the aliphatic portions.
• preferred esters are derived from the saturated aliphatic alcohols or acids of ten or fewer carbon atoms or the cyclic or saturated aliphatic cyclic alcohols and acids of 5 to 10 carbon atoms.
• Particularly preferred aliphatic esters are those derived from lower alkyl acids and alcohols.
• phenyl or lower alkyl phenyl esters are also preferred.
• Amides has the meaning classically accorded that term in organic chemistry. In this instance it includes the unsubstituted amides and all aliphatic and aromatic mono- and di- substituted amides.
• preferred amides are the mono- and di-substituted amides derived from the saturated aliphatic radicals of ten or fewer carbon atoms or the cyclic or saturated aliphatic-cyclic radicals of 5 to 10 carbon atoms.
• Particularly preferred amides are those derived from substituted and unsubstituted lower alkyl amines.
• amides derived from the substituted and unsubstituted phenyl or lower alkylphenyl amines. Unsubstituted amides are also preferred.
• Acetals and ketals include the radicals of the formula-CK where K is (-OR) 2 .
• R is lower alkyl.
• K may be -0R.0- where R 7 is lower alkyl of 2-5 carbon atoms, straight chain or branched.
• a pharmaceutically acceptable salt may be prepared for any compounds in this invention having a functionality capable of forming such-salt, for example an acid functionality.
• a pharmaceutically acceptable salt is any salt which retains the activity of the parent compound and does not impart any deleterious or untoward effect on the subject to which it is administered and in the context in which it is administered.
• Pharmaceutically acceptable salts may be derived from organic or inorganic bases.
• the salt may be a mono or polyvalent ion. Of particular interest are the inorganic ions, sodium, potassium, calcium, and magnesium.
• Organic salts may be made with amines, particularly ammonium salts such as mono-, di- and trialkyl amines or ethanol amines. Salts may also be formed with caffeine, tromethamine and similar molecules.
• salts are those formed with inorganic acids such as hydrochloric acid, sulfuric acid or phosphoric acid. Any of a number of simple organic acids such as mono-, di- or tri- acid may also be used.
• Some of the compounds of the present invention may have trans and cis (E and Z) isomers.
• the compounds of the present invention may contain one or more chiral centers and therefore may exist in enantiomeric and diastereomeric forms .
• Y is phenyl, pyridyl, 2-thiazolyl, thienyl, or furyl, more preferably phenyl.
• the phenyl group is 1,4 (para) substituted by the L ⁇ and A-B groups, and where the pyridine ring is 2,5
• X is [C(R 1 ) 2 ] n and n is 1, and also 5 where X is 0 or S (chroman and thiochroman 6 derivatives).
• the R j groups are preferably H or CH 3 .
• the R 3 ⁇ group is preferably hydrogen.
• the A-B group of the preferred compounds is o (CH 2 ) n -COOH or (CH 2 ) n -C00R 8 , where n and R vom are defined 1 as above. Even more preferably n is zero and R 8 is 2 lower alkyl, or n is zero and B is COOH or a 3 pharmaceutically acceptable salt thereof. 1 Referring now to the W group in Formula 1, this
• a W group does not necessarily have to i be present in the compounds of the invention, 2 although preferably at least one W group is 3 nevertheless present.
• the W group is preferably located in the s position adjacent to the A-B group; preferably the 6 A-B group is in para position in the phenyl ring 7 relative to the "amide" moiety, and therefore the W s group is preferably in meta position relative to the 9 amide moiety.
• Preferred W groups are F, NO-, 7 Br, I, CF 3 , N 3 , and OH.
• the presence of one or two 8 fluoro substituents in the Y group is especially 9 preferred.
• the fluoro 0 substituents preferably are in the ortho and ortho' 1 positions relative to the A-B group, which is 2 preferably COOH or COOR 8 . 3
• the most preferred compounds of the invention are shown in Table 1, with reference to Formulas 4 and 5.
• the compounds of this invention may be administered systemically or topically, depending on such considerations as the condition to be treated, need for site-specific treatment, quantity of drug to be administered, and numerous other considerations.
• it will generally be preferred to administer the drug topically though in certain cases such as treatment of severe cystic acne or psoriasis, oral administration may also be used.
• Any common topical formulation such as a solution, suspension, gel, ointment, or salve and the like may be used. Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example. Remington's Pharmaceutical Science, Edition 17, Mack Publishing Company, Easton, Pennsylvania.
• these compounds could also be administered as a powder or spray, particularly in aerosol form. If the drug is to be administered systemically, it may be confected as a powder, pill, tablet or the like or as a syrup or elixir suitable ⁇ for oral administration. For intravenous or
• Treatment of dermatoses or any other indications 7 known or discovered to be susceptible to treatment 8 by retinoic acid-like compounds will be effected by 9 administration of the therapeutically effective dose 0 of one or more compounds of the instant invention. 1
• a therapeutic concentration will be that concentration which effects reduction of the 3 particular condition, or retards it expansion.
• the compound potentially may be 5 used in prophylactic manner to prevent onset of a 6 particular condition.
• a useful therapeutic or prophylactic 8 concentration will vary from condition to condition 9 and in certain instances may vary with the severity 0 of the condition being treated and the patient's 1 susceptibility to treatment. Accordingly, no single 2 concentration will be uniformly useful, but will 3 require modification depending on the particularities of the disease being treated. Such concentrations can be arrived at through routine experimentation. However, it is anticipated that in the treatment of, for example, acne, or similar dermatoses, that a formulation containing between 0.01 and 1.0 milligrams per mililiter of formulation will constitute a therapeutically effective concentration for total application. If administered systemically, an amount between 0.01 and 5 mg per kg per day of body weight would be expected to effect a therapeutic result in the treatment of many disease for which these compounds are useful.
• retinoid-like activity of the compounds of the invention can be confirmed in assays wherein ability of the compound to bind to retinoid receptors is measured.
• RAR and RXR retinoic acid receptors
• mammals and other organisms.
• sub-types RAR ⁇ , RAR ⁇ , RAR r , RXR ⁇ , RXR ⁇ and RXR r ) the distribution of which is not uniform in the various tissues and organs of mammalian organisms.
• RXR ⁇ , RXR ⁇ and RXR r receptor subtypes are included in RXR ⁇ , RXR ⁇ and RXR r receptor subtypes.
• the wash buffer consisted of lOOmM 9 KCI, lOmM Tris and either 5mM CHAPS (RXR , ⁇ , r) or 0 0.5% Triton X-100 (RAR ⁇ , ⁇ , r).
• the mixture was 1 vortexed and incubated for 10 minutes at 4°C, centrifuged and the supernatant removed.
• the 3 hydroxyapitite was washed three more times with the appropriate wash buffer.
• the receptor-ligand complex was adsorbed by the hydroxyapitite.
• the amount of receptor-ligand complex was determined by liquid scintillation counting of hydroxyapitite pellet. After correcting for non-specific binding, IC 50 values were determined.
• the IC 50 value is defined as the concentration of competing ligand needed to reduce specific binding by 50%.
• the IC 50 value was determined graphically from a loglogit plot of the data.
• the K d values were determined by application of the Cheng-Prussof equation to the IC 50 values, the labeled ligand concentration and the K d of the labeled ligand.
• Table 2 shows the results of the ligand binding assay for certain exemplary compounds of the invention.
• RPMI 8226 is a human hematopoietic cell line obtained from the peripheral blood of a patient with multiple myeloma. The cells resemble the lymphoblastoid cells of other human lymphocyte cell lines and secrete ⁇ -type light chains of immunoglobulin.
• RPMI-8226 cells are grown in RPMI medium (Gibco) supplemented with 10% fetal bovine serum, glutamine and antibiotics. The cells were maintained as suspension cultures grown at 37°C in a humidified atmosphere of 5% C0 2 in air.
• ME-180 is a human epidermoid carcinoma cell line derived from the cervix. The tumor was a highly invasive squamous cell carcinoma with irregular cell clusters and no significant keratinization.
• ME-180 cells were grown and maintained in McCoy's 5a medium (Gibco) supplemented with 10% fetal bovine serum, glutamine and antibiotics. The cells were maintained as monolayer cultures grown at 37°C in a humidified atmosphere of 5% C0 2 in air. The cells were diluted to a concentration of 1 x lOVml twice a week. AML-193 was established from the blast cells classified as M5 Acute Monocyte Leukemia.
• GM-CSF granulocyte colony-stimulation factor
• AML-193 cells were grown and maintained in Iscove's modified Dulbecco's medium supplemented with 10% fetal bovine serum, glutamine and antibiotics with 5 ⁇ g/ml insulin (Sigma Chemical Co.) and 2 ng/ml rh GM-CSF (R and D Systems). The cells were diluted to a concentration of 3 x lOVml twice a week. Incorporation of 3 H-Thymidine The method used for determination of the incorporation of radiolabeled thymidine was adapted from the procedure described by Shrivastav et al.
• RPMI-8226 cells were plated in a 96 well round bottom microtiter plate (Costar) at a density of 1,000 cells/well. To appropriate wells, retinoid test compounds were added at the final concentrations indicated for a final volume of 150 ⁇ l/well. The plates were incubated for 96 hours at 37°C in a humidified atmosphere of 5% C0 2 in air. Subsequently, 1 ⁇ Ci of [5'- 3 H]-thymidine (Amersham, U.K. 43 Ci/mmol specific activity) in 25 ⁇ l culture medium was added to each well and the cells were incubated for an additional 6 hours. The cultures were further processed as described below.
• ME-180 wells harvested by trypsinization were plated in a 96 well flat bottom microtiter plate (Costar) at a density of 2,000 cells/well. The cultures were treated as described above for RPMI 8226 with the following exceptions. After incubation with thymidine the supernatant was carefully removed, and the cells were washed with a 0.5 mM solution of thymidine in phosphate buffered saline. ME180 cells were briefly treated with 50 ⁇ l of 2.5% trypsin to dislodge the cells from the plate. AML-193 cells were plated in a 96 well round bottom microtiter plate (Costar) at a density of 1,000 cells/well.
• retinoid test compounds were added at the final concentrations indicated for a final volume of 150 ⁇ l/well.
• the plates were incubated for 96 hours at 37°C in a humidified atmosphere of 5% C0 2 in air. Subsequently, 1 ⁇ Ci of [5'- 3 H]-thymidine (Amersham, U.K., 43 Ci/mmol specific activity) in 25 ⁇ l culture medium was added to each well and the cells were incubated for an additional 6 hours. All cells lines were then processed as follows: the cellular DNA was precipitated with 10% trichloroacetic acid onto glass fiber filter mats using a SKATRON multi-well cell harvester (Skatron Instruments, Sterling VA) .
• Radioactivity incorporated into DNA was measured by liquid scintillation counting.
• the numbers represent the mean disintegrations per minute of incorporated thymidine from triplicate wells ⁇ SEM.
• exemplary compounds 6, 8, 12, 14 and 20 of the invention caused significant decrease in the proliferation of the tumor cell lines (as measured by incorporation of radioactive labeled thymidine) in the 10 "11 to 10 ⁇ 6 molar concentration range of the respective test compound.
• SPECIFIC EMBODIMENTS The compounds of this invention can be made by the synthetic chemical pathways illustrated here. The synthetic chemist will readily appreciate that the conditions set out here are specific embodiments which can be generalized to any and all of the compounds represented by Formula 1.
• the process of preparing compounds of the invention involves the formation of an amide by the reaction of a compound of the general Formula 2 with a compound of general Formula 3, or by the reaction of a compound of general Formula 2a with a compound of general Formula 3a as these formulas are defined in the Summary section of the present application for patent.
• the carboxylic acid, or its "activated form” is attached to the 2 or 3 position of the tetrahyronaphthalene, and to the 6 or 7 position of the chroman, thiochroman or tetrahydroquinoline moieties. In the pref rred compounds of the invention the attachment is to the 2 position of tetrahydronaphthalene and to the 6 position of chroman, thiochroman or tetrahydroquinoline.
• the term "activated form" of the carboxylic acid should be understood in this regard as such derivative of the carboxylic acid which is capable of forming an amide when reacted with a primary amine of Formula 3.
• the activated form of a carboxylic acid is a derivative (Formula 3a) that is capable of forming ⁇ an amide when reacted with a primary amine of
• esters of the carboxylic acid particularly active esters, where the alcohol moiety
• the acid chlorides of Formula 2 (or of Formula 3a) can be prepared by traditional methods from the 4 corresponding esters (X ⁇ is for example ethyl) by 5 hydrolysis and treatement with thionyl chloride 6 (S0C1 2 ).
• the acid chlorides of Formula 2 (or of 7 Formula 3a) can also be prepared by direct treatment of the carboxylic acids with thionyl chloride, where 9 the carboxylic acid, rather than an ester thereof is available commercially or by a known synthetic 1 procedure.
• the acid chlorides of Formula 2 are typically reacted with the amine of Formula 3 (or amine of Formula 2a) in an inert solvent, such as methylene chloride, in the presence of an acid acceptor, such as pyridine.
• the carboxylic acids themselves in accordance with Formula 2 (or Formula 3a) are also suitable for amide formation when reacted with an amine, a catalyst (4-dimethylaminopyridine) in the presence of a dehydrating agent, such as dicyclohexylcarbodiimide (DCC) or more pereferably 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide hydrochloride (EDC).
• DCC dicyclohexylcarbodiimide
• EDC 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide hydrochloride
• Reaction Scheme 2 ⁇ Reaction Schemes 1 and 2 provide examples for
• Ethyl 9 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-3-aminonaphth 0 alene-2-carboxylate (Compound C) is also diazotized 1 and reacted with HBF 4 to provide ethyl 2 5,6,7,8-tetrahydro-5,5,8,8-tetra-methyl-3-fluoronaph 3 thalene-2-carboxylate (Compound G) which serves 4 either per se or after saponification as a reagent 5 in accordance with Formula 2. 6 ⁇ 5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-hydroxy-
• Reaction Scheme 5 ⁇ Reaction Schemes 3, 4 and 5 provide examples for
• Compound R is 2 converted to a trifluoromethyl function by treatment 3 with sodium trifluoroacetate in the presence of 4 cuprous iodide catalyst and l-methyl-2-pyrrolidinone 5 (NMP), and the carboxylate ester group is saponified 6 to yield 7 2,2,4,4-tetramethyl-8-trifluoromethylchroman-6-carbo 8 xylic acid (Compound S) .
• Compound S is within the 9 scope of Formula 2 and is suitable per se or as the o acid chloride or in other "activated" form to react 1 with the amines of Formula 3 to yield the carbamoyl 2 (amide) compounds of the invention.
• Compound Y is brominated with bromine 8 in acetic acid to give 9 2,2,4,4,8-pentamethyl-6-bromochroman (Compound Z) 0 which is reacted with t-butyl lithium and thereafter 1 with carbon dioxide to give 2 2,2,4,4, 8-pentamethylchroman-6-carboxylic acid 3 (Compound A-ft . 4
• Reaction Scheme 5 illustrates the synthesis of 5 4,4-dimethyl-8-bromochroman-6-carboxylic acid 6 (Compound B x ) by bromination of 7 4,4,-dimethyl-chroman-6-carboxylic acid which is ⁇ available in accordance with the teachings of United 9 States Patent No.
• amine compounds are, generally speaking, available in accordance with the state-of-the-art. as described in the scientific and patent literature. More specifically, the amine compounds of Formula 3 can be prepared as described in the scientific and patent literature, or from known compounds of the literature, by such chemical reactions or transformations which are within the skill of the practicing organic chemist.
• Reaction Scheme 6 illustrates examples for the preparation of amine compounds of Formula 3 (where Y is phenyl) from commercially available starting materials (Aldrich Chemical Company, or Research Plus, Inc. The illustrated compounds of Formula 3 are used for the synthesis of several preferred compounds of the invention.
• Reaction Scheme 6 -continue d Thus, in accordance with Reaction Scheme 6, 3-nitro-6-methyl-fluorobenzene (Aldrich) is subjected to oxidation, conversion of the resulting carboxylic acid to an acid chloride and thereafter to an ethyl ester, followed by reduction of the nitro group, to yield ethyl 2-fluoro-4-amino-benzoate (Compound C x ) .
• 2,3,5,6-Tetrafluoro-4-amino-benzoic acid is esterified by treatment with ethanol in the presence of l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and 4-dimethylaminopyridine in CH 2 C1 2 to give ethyl 2,3 , 5,6-tetrafluoro-4-amino-benzoate (Compound G, ) .
• reagents in accordance with Formula 3 are nitro, fluoro, chloro, bromo and trifluoromethyl derivatives of amino substituted heteroaryl carboxylic acids, or their lower alkyl esters, such as ethyl 2-amino-4-chloropyridine 2-carboxylate, ethyl 5-amino-3-chloropyridine 5-carboxylate, and 3,4-dibromo-5-aminothiophene-2-carboxylic acid.
• the 1 latter examples can be prepared by respective
• the carbamoyl (amide) compounds of the invention can be s converted into thiocarbamoyl (thioamide) compounds 6 of the invention where with reference to Formula 1 Z 7 is S, by reacting the carbamoyl (amide) compound 8 with 9 2,4-bis(4-methoxyphenyl)-l,3-dithia-2,4-diphosphetan e-2,4-disulfide (Lawesson's reagent).
• This reaction 1 is illustrated in Reaction Scheme 7 for two specific examples for the compounds of the invention.
• Reaction Scheme 7 In Reaction Scheme 7 one starting material ethyl 4-[5' ,6 ' ,7 ' ,8 '-tetrahydro-5' ,5' ,8 ' , 8 '-tetramethylnap hthalen-2-yl)carbamoyl]benzoate (Compound 1 1 ) is obtained in accordance with the teachings of Kagechika et al. J. Med Chem. 1988 31, 2182 - 2192. The other starting material, ethyl
• Reaction Scheme 10 disclose examples for the preparation of carbamoyl (amide) compounds of the invention, first by a coupling reaction of a compound of Formula 2 with a compound of Formula 3 , followed by one or more reactions performed on the carbamoyl (amide) compound that has been first obtained directly in the coupling reaction.
• a coupling reaction of a compound of Formula 2 with a compound of Formula 3 followed by one or more reactions performed on the carbamoyl (amide) compound that has been first obtained directly in the coupling reaction.
• Reaction Scheme 8 5,6,7, 8-tetrahydro-5,5,8, 8-tetramethyl- 3-me hoxymethoxynaphthalene-2-carboxylie acid (Compound K) is coupled with ethyl
• Reaction Scheme 10 discloses the example of 6 converting 2,2,4,4-tetramethyl-8-nitrochroman-6- carboxylic acid (Compound V) into the corresponding ⁇ acid chloride by treatment with thionyl chloride, 9 followed by coupling with ethyl 0 4-amino-2-fluorobenzoate (Compound C x ) and 1 hydrogenation to yield ethyl 2 2-fluoro-4-[ (2' ,2 ' ,4 ' ,4'-tetramethyl-8 '-amino-6 '-chr 3 omanyl)carbamoyl]benzoate (Compound N x ) .
• the acid chloride of Formula 2 is reacted with sodium azide in acetone to yield the azide compound of Formula 6.
• the azide of Formula 6 is heated in a polar high boiling solvent, such as t-butanol, to provide the intermediate isocyanate of Formula 7 , which is hydrolyzed to yield a compound of Formula 2a.
• Reaction Scheme 12 1 Reaction Scheme 12 illustrates examples for
• Carboxylic acids are typically esterified by refluxing the acid in a solution of the appropriate alcohol in the presence of an acid catalyst such as hydrogen chloride or thionyl chloride.
• an acid catalyst such as hydrogen chloride or thionyl chloride.
• the carboxylic acid can be condensed with the appropriate alcohol in the presence of dicyclohexylcarbodiimide and dimethylaminopyridine. The ester is recovered and purified by conventional means. Acetals and ketals are readily made by the method described in March, "Advanced Organic
• a means for making compounds where A is (CH 2 ) q (q is 1 - 5) is to subject the compounds of Formula 1, where B is an acid or other function, to homologation, using the well known Arndt-Eistert method of homologation, or other known homologation procedures. Similar homologations (and several of the other herein mentioned synthetic transformations) can be transformed on the reagent of Formula 3.
• A is an alkenyl group having one or more double bonds
• A is an unsaturated carbon chain
• such compounds where A is an unsaturated carbon chain can be obtained by synthetic schemes well known to the practicing organic chemist; for example by Wittig and like reactions, or by introduction of a double bond by elimination of halogen from an alpha-halo-carboxylic acid, ester or like carboxaldehyde.
• Compounds of the invention where ⁇ the A group has a triple (acetylenic) bond can be
• ⁇ Formula 1 are readily obtainable from the o corresponding esters.
• Basic saponification with an 1 alkali metal base will provide the acid.
• an ester of Formula 1 may be dissolved in a 3 polar solvent such as an alkanol, preferably under 4 an inert atmosphere at room temperature, with about s a three molar excess of base, for example, potassium 6 or lithium hydroxide.
• the solution is stirred for 7 an extended period of time, between 15 and 20 hours, s cooled, acidified and the hydrolysate recovered by 9 conventional means.
• the amide in Formula 1 B is CONR 9 R 10
• One way to prepare such compounds is to convert an acid to an acid chloride and then treat that compound with ammonium hydroxide or an appropriate amine.
• Alcohols are made by converting the corresponding acids to the acid chloride with thionyl chloride or other means (J. March, "Advanced Organic Chemistry", 2nd Edition, McGraw-Hill Book 1 Company) , then reducing the acid chloride with sodium borohydride (March, Ibid, pg. 1124), which gives the corresponding alcohols.
• esters may be reduced with lithium aluminum hydride at reduced temperatures. Alkylating these alcohols with appropriate alky halides under Williamson reaction conditions (March, Ibid, pg. 357) gives the corresponding ethers.
• Aldehydes can be prepared from the corresponding primary alcohols using mild oxidizing agents such as pyridinium dichromate in methylene chloride (Corey, E. J., Schmidt, G., Tet. Lett. , 399, 1979) , or dimethyl sulfoxide/oxalyl chloride in methylene chloride (Omura, K., Swern, D., Tetrahedron, 1978, 3_4, 1651).
• Ketones can be prepared from an appropriate aldehyde by treating the aldehyde with an alkyl Grignard reagent or similar reagent followed by oxidation. Acetals or ketals can be prepared from the corresponding aldehyde or ketone by the method described in March, Ibid, p 810. Compounds of Formula 1 where B is H can be prepared from the corresponding halogenated aromatic compounds, preferably where the halogen is I.
• Methyl 4-Amino-2,6-difluorobenzoate (Compound H- A solution of trifluorobenzoic acid (150 mg, 0.85 mmol, Aldrich) in 0.5 ml of S0C1 2 was heated under reflux for 2h. The reaction mixture was cooled to room temperature, and excess of S0C1 2 was removed under reduced pressure. The residue was dissolved in 1 ml of pyridine and 0.2 ml of methanol. After stirring at room temperature for 30 min, solvent was removed and the residue was purified by column chromatography (ethyl acetate/hexane 1/10) to give methyl trifluoro- benzoate as a colorless oil.
• This oil was then dissolved in 1 ml of CH 3 CN, then a solution of NaN 3 (100 mg, 1.54 mmol) in 0.5 ml of water was added. The reaction mixture was refluxed for two days. Salt was filtered and the remaining solution was concentrated to an oil. This oil was then dissolved in 1 ml of methanol, followed by a catalytic amount of Pd/C (10%, w/w). The reaction mixture was hydrogenated under a hydrogen balloon for 12 h. Catalyst was removed and the solution was concentrated to an oil. After column chromatography (ethyl acetate/hexane 1/3), the title product was obtained as colorless crystals.
• Ethyl 8-Nitro-2,2,4,4-tetramethyl-6-chromanoate (Compound ) Ethyl 2,2,4,4-tetramethyl-6-chromanoate (150 mg, 0.57 mmol) was slowly added to 0.3 ml of cone. H 2 S0 4 at 0 °C. To this mixture was added very slowly 0.03 ml of HN0 3 . The reaction mixture was stirred at 0 °C for 30 min and poured into ice-water. The product was extracted into 5 ml of ethyl acetate, washed with NaHC0 3 (sat.), brine and dried over MgS0 4 .
• Ethyl 2-Fluoro-4-r (2' .2' .4' .4'-tetramethyl-8 '-trifluoromet hylchroman-6'-yl)carbamoyl1 benzoate (Compound 13) Using the same procedure as for ethyl 2-fluoro-4-[ (4' ,4 '-dimethyl-8 '-bromochroman-6 '-yl)ca rbamoyl]benzoate (Compound 9), but using 2,2,4,4-tetramethyl-8-trifluoromethyl-6-chromanoic acid (Compound S, 57 mg, 0.19 mmol) and ethyl 4-amino-2-fluorobenzoate (Compound C lf 35 mg, 0.19 mmol), the title compound was obtained as white solids.
• Ethyl 2-Fluoro-4-T t2'.2'.4'.4'-tetramethyl-8 '-amino- chroman-6 '-yl)carbamoyl]benzoate (Compound N x ) Using 8-nitro-2, 2, 4, 4-tetramethylchroman-6-carboxylic acid (Compound V) and following the same procedure as for the synthesis of ethyl 2-fluoro-4-[ (4' ,4 '-dimethyl-8'-bromochroman-6 '-yl)ca rbamoyl]benzoate (Compound 9), ethyl 2-fluoro-4-[2' ,2' ,4 ' ,4 '-tetramethyl-8 '-nitrochroman- 6 '-yl) ]carbamoylbenzoate was obtained as a white solid.
• This compound (50 mg, 0.12 mmol) was dissolved in 2 ml of methanol. A catalytic amount of Pd/C was added to the solution and the solution was maintained under H 2 atmosphere (hydrogen balloon) for overnight. The catalyst was removed by filtration and the solvent was evaporated to give the title compound as a white solid.
• reaction io mixture was stirred for an additional hour at -78°C.

Priority Applications (14)

Applications Claiming Priority (2)

Publications (2)

Family

ID=24244382

Family Applications (1)

Country Status (20)

Cited By (16)

Families Citing this family (58)

Citations (2)

Family Cites Families (107)

• 1995
  • 1995-11-22 US US08/562,000 patent/US5675024A/en not_active Expired - Lifetime
• 1996
  • 1996-11-18 CN CN96199714A patent/CN1117070C/zh not_active Expired - Lifetime
  • 1996-11-18 NZ NZ323581A patent/NZ323581A/xx unknown
  • 1996-11-18 EP EP96941408A patent/EP0876330B1/en not_active Expired - Lifetime
  • 1996-11-18 BR BR9611758A patent/BR9611758A/pt not_active Application Discontinuation
  • 1996-11-18 DE DE69612303T patent/DE69612303T2/de not_active Expired - Lifetime
  • 1996-11-18 RU RU98111757/04A patent/RU2163906C2/ru not_active IP Right Cessation
  • 1996-11-18 JP JP51985297A patent/JP4112003B2/ja not_active Expired - Lifetime
  • 1996-11-18 AU AU10560/97A patent/AU702499B2/en not_active Ceased
  • 1996-11-18 WO PCT/US1996/018580 patent/WO1997019052A1/en active IP Right Grant
  • 1996-11-18 PT PT96941408T patent/PT876330E/pt unknown
  • 1996-11-18 CA CA002238274A patent/CA2238274C/en not_active Expired - Fee Related
  • 1996-11-18 PL PL96327457A patent/PL186404B1/pl not_active IP Right Cessation
  • 1996-11-18 AT AT96941408T patent/ATE200074T1/de not_active IP Right Cessation
  • 1996-11-18 DK DK96941408T patent/DK0876330T3/da active
  • 1996-11-18 ES ES96941408T patent/ES2157470T3/es not_active Expired - Lifetime
  • 1996-11-18 IL IL12459796A patent/IL124597A/en not_active IP Right Cessation
  • 1996-11-19 KR KR10-1998-0703817A patent/KR100450498B1/ko active IP Right Review Request
• 1997
  • 1997-09-04 US US08/923,864 patent/US5856490A/en not_active Expired - Fee Related
• 1998
  • 1998-05-22 MX MX9804087A patent/MX9804087A/es unknown
  • 1998-10-15 US US09/173,574 patent/US6034244A/en not_active Expired - Fee Related
• 2000
  • 2000-01-25 US US09/491,176 patent/US6124455A/en not_active Expired - Fee Related
  • 2000-08-04 US US09/634,733 patent/US6342602B1/en not_active Expired - Fee Related
• 2001
  • 2001-05-31 GR GR20010400830T patent/GR3035979T3/el not_active IP Right Cessation

Patent Citations (2)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events